It is 1935. Dorothy Hodgkin is 25. She has just taken the first X-ray photograph of an insulin crystal.
The image is noise. Tiny specks on film standing in for 788 atoms. She will spend the next three decades working out exactly what those specks mean.
In 1935, X-ray crystallography meant a dark room, a tube, a crystal, and film. You take the picture. Then you do the math.
She learned the method at Cambridge under J.D. Bernal. He taught her the physics, and he taught her a refusal to round a number when it had to be exact.
She chose insulin because the molecule mattered. The prevailing medical view treated diabetes as a symptom. Hodgkin read it as a structural problem.
During World War II, she set insulin aside for a stretch to study penicillin.
The chemistry establishment was certain that a particular four-atom structure in penicillin, a beta-lactam ring, simply could not exist. The strain, they argued, would snap the molecule apart.
Hodgkin mapped it and showed they were wrong. The strain was the point. That exact tension was what made the molecule lethal to bacteria.
There is a quiet satisfaction in settling an argument with physics. The chemists debated theory. Hodgkin pointed at the film: the atoms sit where they sit.
In 1948 she took on vitamin B12. At 181 atoms, its complexity ran past what hand calculation could reach, however massive the effort.
But the hardware was catching up. Working with Alan Turing's Pilot ACE machine, Hodgkin saw what most chemists missed. Crystallography was, at bottom, a math problem waiting for enough computing power.
She learned to program in the earliest languages just to process her own data. By 1954 she had solved B12.
She won the Nobel Prize in chemistry in 1964. Most people take the victory lap. Hodgkin went straight back to the insulin puzzle.
By 1960, Hodgkin was 50 and living with severe rheumatoid arthritis.
The autoimmune disease was actively destroying the small joints in her hands and wrists. For someone whose work meant aligning microscopic crystals and adjusting delicate equipment, that was an enormous physical obstacle.
Instead of stopping, she built a lever-and-pulley system to trigger the X-ray switch when her fingers no longer could. She taped splints to her hands and kept working.
Why go back to insulin at all? She had the Nobel. Her legacy was secure either way. She simply meant to keep the promise she had made herself at 25, and not let the puzzle win.
She raised the funding, got IBM to donate machine time, and pushed the math forward. In September 1969, 34 years after that first photograph, she and her team published the structure in Nature.
She had placed 788 atoms locking into a hexamer. She finally knew exactly where the zinc sat.
She solved roughly 100 structures over her career. Since then, the field has mapped more than 250,000 proteins. The Protein Data Bank we rely on today exists because of the foundation she laid.
A 34-year timeline might suggest a scientist working alone in a dark room. Hodgkin worked the opposite way, in deep collaboration.
In an era of strict academic formality, she had her students call her "Dorothy." When the Nobel money came, she gave most of it away to international scholarships and peace work.
Her husband was a member of the Communist Party, which led the United States to bar her from the country during the Cold War. She made the CIA issue waivers so she could attend scientific conferences.
She went anyway.
Today's GLP-1s and peptide medicines exist because of the patience of the people who built the tools. The treatments we have now are the direct result of a woman who refused to accept an incomplete answer until the film gave it up.
This article uses primary sources and reviews to separate mechanism, human evidence, and context.
Springer NatureStructure of rhombohedral 2 zinc insulin crystals. Read source
Documenting Hodgkin's crystallographic determination of insulin's molecular structure.
Understanding how X-ray crystallography revealed the 3D structure of a peptide hormone.
Clinical information about insulin therapy or dosing.
Peptide therapeutics: current status and future directions. Read source
Connecting Hodgkin's structural work to the modern era of peptide drug design.
Understanding how structural biology enabled today's peptide therapeutics.
Determining whether a specific product is approved, safe, or right for someone.
The future of peptide-based drugs. Read source
Supporting the throughline from insulin's structure to modern peptide-based drug design.
A broad view of how peptide structure informs drug design.
Clinical outcome data or treatment recommendations.
